Levetiracetam Tablet
Product Images NDC 80425-0566

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 80425-0566). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Advanced Rx Of Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam 500mg # 120 (Levetiracetam 500mg 80425 0566 01)

FDA Label Image

Levetiracetam 500mg #30 (Levetiracetam 500mg 80425 0566 02)

This is a description of LevETIRACETAM 500mg Tablet #30, with the NDC (National Drug Code) 80425-0566-02. The expiration date is 12/31/2030, and it is manufactured by TRIS PHARMA INC. It is a prescription medication.*

FDA Label Image

Levetiracetam 500mg # 60 (Levetiracetam 500mg 80425 0566 03)

This is a product description for Leveteracetam 500mg tablets, which is an anticonvulsant medication used to treat seizures. The tablets come in a pack of 60 and have an expiration date of 12/31/2030. The manufacturer is Tris Pharma Inc. The product is only available by prescription.*

FDA Label Image

Levetiracetam 500mg #90 (Levetiracetam 500mg 80425 0566 04)

This is a label for Levitiracetam 500mg tablets, with a quantity of 90 tablets. The NDC number is 80425-0566-04 and the expiration date is 12/31/2030. The source NDC is 27808-0264-02. The medication is manufactured by Tris Pharma Inc. It is a prescription medication.*

FDA Label Image

Structure Formula (Levetiracetam Tablets 1)

FDA Label Image

Figure1 (Levetiracetam Tablets 2)

This text provides information on the percentage of patients involved in a study comparing the efficacy of Levetiracetam at different doses and a placebo. The data shows that 9% of patients received placebo, while the rest were divided into two groups receiving different doses of Levetiracetam (1000 mg/day and 3000 mg/day). The sample size for each group is also provided. This information can be useful for understanding the distribution of participants in the study.*

FDA Label Image

Figure2 (Levetiracetam Tablets 3)

This is a medical study data showing the percentage of patients in the placebo and Levetiracetam (2000 mg/day) groups. The placebo group had 63% of patients, while the Levetiracetam group had 35.2%. The study included a total of 111 patients in the placebo group and 105 patients in the Levetiracetam group.*

FDA Label Image

Figure3 (Levetiracetam Tablets 4)

FDA Label Image

Figure4 (Levetiracetam Tablets 5)

This appears to be a list showing percentages and numbers related to a study comparing the effects of Placebo and Levetiracetam on a certain parameter. The data includes percentages such as 5%, 3%, 2%, etc., and participant counts for each group. The text seems to be part of a research or clinical trial data report.*

FDA Label Image

Figure5 (Levetiracetam Tablets 6)

FDA Label Image

Figure6 (Levetiracetam Tablets 7)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.